Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Aims</h3><p>To assess the efficacy and safety of polyethylene glycol loxenatide (PEX168), a new glucagon‐like peptide receptor agonist, as an add‐on to metformin therapy in Chinese patients with type 2 diabetes mellitus (T2DM).</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Materials and methods</h3><p>This was a multicenter, randomized, double‐blind, placebo‐controlled phase 3b trial. After metformin monotherapy (≥1500 mg/day) for ≥8 weeks, patients with uncontrolled T2DM [glycated hemoglobin (HbA1c) 7.0%–10.5%] from 44 sites were randomized (1:1:1) to metformin + placebo, metformin + PEX168 100 μg, and metformin + PEX168 200 μg. The core treatment period lasted for 24 weeks, followed by a 28‐week extension period. The primary endpoint was the change in HbA1c levels at week 24. The main secondary endpoint was the proportion of patients with HbA1c <7.0% at week 24.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>The least‐square mean (standard error) change in HbA1c levels was significantly greater (P < 0.001 for superiority) in PEX168 groups [−1.16% (0.08%) and − 1.14% (0.08%) with 100 μg and 200 μg, respectively] than in the placebo group [0.35% (0.08%)]. The proportion of patients with HbA1c <7.0% at week 24 was significantly higher in the PEX168 100 μg (37.4%) and PEX168 200 μg (40.6%) groups than in the placebo group (16.8%, both P < 0.001). The gastrointestinal reactions were mild; the risks of hypoglycemia and weight gain did not increase. Anti‐PEX168 antibodies were noted in less than 2% of patients. No treatment‐emergent SAEs occurred.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion</h3><p>The subcutaneous injection of PEX168 once a week can effectively, continuously, and safely improve HbA1c levels in patients with T2DM when combined with metformin.</p><p>This article is protected by copyright. All rights reserved.</p></section>

Adding vitamin D3 to the dipeptidyl peptidase‐4 inhibitor saxagliptin has the potential to protect β‐cell function in LADA patients: A 1‐year pilot study

Adding Vitamin D3 to the Dipeptidyl Peptidase-4 Inhibitor Saxagliptin Has the Potential to Protect β-Cell Function in LADA Patients: A One-Year Pilot Study.

Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial

Dipeptidyl Peptidase 4 Inhibitor Sitagliptin Maintains Β-Cell Function in Patients with Recent-Onset Latent Autoimmune Diabetes in Adults: One Year Prospective Study.

Saxagliptin/dapagliflozin is non‐inferior to insulin glargine in terms of β‐cell function in subjects with latent autoimmune diabetes in adults: A 12‐month, randomized, comparator‐controlled pilot study

Altered T‐cell Subsets and Transcription Factors in Latent Autoimmune Diabetes in Adults Taking Sitagliptin, a Dipeptidyl Peptidase‐4 Inhibitor: A 1‐year Open‐label Randomized Controlled Trial

Vitamin D supplementation could enhance the effectiveness of glibenclamide in treating type 2 diabetes by improving the function of pancreatic β-cells through the NF-κB pathway

Saxagliptin combined with additional oral antihyperglycaemic agents in drug-naive diabetic patients with high glycosylated haemoglobin: A 24-week, multicentre, randomized, open-label, active parallel-controlled group clinical trial in China (SUCCESS)

Author Response for "saxagliptin Combined with Additional Oral Antihyperglycemic Agents in Drug‐naive Diabetic Patients with High Glycosylated Hemoglobin: a 24‐week, Multicenter, Randomized, Open‐label, Active Parallel‐controlled Group Clinical Trial in China (SUCCESS)"

Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin

Islet Function And Insulin Sensitivity In Latent Autoimmune Diabetes In Adults Taking Sitagliptin: A Randomized Trial

Blood Glucagon Levels Predict the Hemoglobin A1c Response to Saxagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin.

Saxagliptin Add-on Therapy in Chinese Patients with Type 2 Diabetes Inadequately Controlled by Insulin with or Without Metformin: Results from the SUPER Study, a Randomized, Double-Blind, Placebo-Controlled Trial

The efficacy and safety of Diptptidyl peptidase-4 inhibitors combined with insulin in patients with autoimmune diabetes: A updated meta-analysis

Effect of large doses of parenteral vitamin D on glycaemic control and calcium/phosphate metabolism in patients with stable type 2 diabetes mellitus: a randomised, placebo-controlled, prospective pilot study

The efficacy of saxagliptin in T2DM patients with non-alcoholic fatty liver disease: preliminary data.

Rosiglitazone Combined with Insulin Preserves Islet Beta Cell Function in Adult-Onset Latent Autoimmune Diabetes (Lada).

Therapeutic effects of pioglitazone combined with insulin on newly diagnosed latent autoimmune diabetes in adult

Dapagliflozin As Add-on Therapy in Asian Patients with Type 2 Diabetes Inadequately Controlled on Insulin with or Without Oral Antihyperglycemic Drugs: A Randomized Controlled Trial.

Efficacy and safety of polyethylene glycol loxenatide as add‐on to metformin in patients with type 2 diabetes: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3b trial